retatrutide nonalcoholic fatty liver disease trial nash Fatty Liver Disease and Fibrosis (NASH) Clinical Trial retatrutide nonalcoholic fatty liver disease

While there has been a lot in the news about GLP-1 drugs that is negative, more and more patients are using them because the positive effects and outcomes overwhelmingly outweigh the negative

Results can vary from person to person, depending on factors like diet, physical activity, medication adherence, and starting body weight

Some Florida dentists say their patients on weight-loss medications report these concerns

As amylin and GLP-1 target different populations of neurons in the DVC 20 , this suggests that combination drug therapies affecting both systems may provide a greater magnitude and sustainable degree of weight loss compared to monotherapies due to a reduced likelihood of tachyphylaxis 21,22,23

In response, the brand developed a GLP-1 Support Menu created with a registered dietitian designed to make it easier for guests to stay nourished with options that are high in protein and fiber and contain zero grams of added sugar. Werner said these changes make sense but cautioned against the belief that simply adding more protein is healthier